| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Groundbreaking Study reveals a 76% drop in hospital readmissions and a 41% decrease in Emergency Department visits, underscoring SHL and SmartHeart®'s pivotal role in remote cardiac care
SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial. The randomized clinical trial showcased, among other things, how SHL's SmartHeart® 12-lead ECG technology can significantly reduce hospital readmissions and ED visits for post-MI (heart attack) patients at home.
Posted In: SHLT
